← FDA DRUG APPROVALS

FDA ANDA · ANDA075036

CISPLATIN

Sponsor: HIKMA

APPLICATION
ANDA075036
TYPE
ANDA
ORIGINAL APPROVAL
2000-11-07
LATEST ACTION
2018-09-24
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

CISPLATINPrescription
CISPLATIN 1MG/ML · INJECTABLE · INJECTION

Approval history

2018-09-24Labeling · Supplement 12 · standardAP
2012-03-15Labeling · Supplement 11AP
2012-01-30Labeling · Supplement 9AP
2011-03-08Labeling · Supplement 6AP
2004-06-21Labeling · Supplement 3AP
2004-06-21Supplement · Supplement 2AP
2001-05-14Manufacturing (CMC) · Supplement 1AP
2000-11-07OriginalLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →